Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03480659|
Recruitment Status : Terminated (Technical problem with plasma blood samples obtained from the patients)
First Posted : March 29, 2018
Last Update Posted : April 20, 2022
A central challenge in the fight against breast cancer is how to detect disease in a noninvasive manner before it is detectable by imaging methods. Although inroads have been made with more sensitive imaging techniques for earlier detection of breast cancer, these techniques are limited by the size of lesion that could be detected. Alternatively, several blood proteomic biomarkers have been proposed but none offer as of yet sufficient predictive power. Consequently, effective non-invasive tools as prognostic indicators and biomarkers of breast cancer are urgently needed.
The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in breast cancer patients.
|Condition or disease|
|Breast Cancer Breast Cancer Female|
|Study Type :||Observational|
|Actual Enrollment :||165 participants|
|Official Title:||Breast Cancer Screening Using DNA Methylation Changes in Circulated Tumor, PBMC and T-cells DNA.|
|Actual Study Start Date :||June 1, 2018|
|Actual Primary Completion Date :||August 1, 2021|
|Actual Study Completion Date :||September 1, 2021|
Early stage luminal A and triple negative breast cancer [TNBC] (estrogen receptor-negative (ER-), progesterone receptor-negative (PR-) and HER2-negative (HER2-)
Age matched control females
- DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of breast cancer [ Time Frame: 6 months to 1 year ]
We will develop the linear model and a threshold value differentiating breast cancer from control based on the 100 patient training set. The model will be provided to the researchers:
Methylation score=CG1*b1+CG2*b2+ CG3*b3 + e
CG1 is the methylation value of the first CG b1 is the regression coefficient for the first CG and e equals the intercept.
We will develop the regression coefficient and intercept as well as the DNA methylation values for each patient for each CG. We will first compute the polygenic methylation score for each patient. Then based on the computer threshold based on the training cohort will call the samples as breast cancer or not.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03480659
|Kazakh Institute of Oncology and Radiology|